Genmab A/S (GMAB) |
|
36.445 0.19 (0.52%)
|
09-26 15:29 |
|
Open: |
36.48 |
Pre. Close: |
36.255 |
|
High:
|
36.71 |
Low:
|
36.4 |
|
Volume:
|
353,446 |
Market Cap:
|
23,803(M) |
|
|
|
Technical analysis |
as of: 2023-09-26 2:49:30 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 44.48 One year: 46.17 |
| Support: |
Support1: 35.75 Support2: 29.75 |
| Resistance: |
Resistance1: 38.08 Resistance2: 39.52 |
| Pivot: |
37.18  |
| Moving Average: |
MA(5): 36.55 MA(20): 37.52
MA(100): 38.79 MA(250): 39.36 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.3 |
| Stochastic oscillator: |
%K(14,3): 15.1 %D(3): 14.1 |
| RSI: |
RSI(14): 43 |
| 52-week: |
High: 47.5 Low: 31.39 |
| Average Vol(K): |
3-Month: 485 (K) 10-Days: 446 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GMAB ] has closed above bottom band by 26.6%. Bollinger Bands are 17.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
36.39 - 36.59 |
36.59 - 36.78 |
|
Low:
|
35.22 - 35.49 |
35.49 - 35.73 |
|
Close:
|
35.86 - 36.26 |
36.26 - 36.61 |
|
Company Description |
|
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark. |
Headline News |
Tue, 26 Sep 2023
Positive Outlook for Genmab with Moderate Buy Rating and 4630 ... - Best Stocks
Tue, 26 Sep 2023
Genmab Announces European Commission Approval of TEPKINLY ... - BioSpace
Mon, 25 Sep 2023
AbbVie, Genmab: EU Approves TEPKINLY For Adults With R/R ... - RTTNews
Mon, 25 Sep 2023
AbbVie, Genmab: EU Approves TEPKINLY For Adults With R/R ... - Nasdaq
Mon, 25 Sep 2023
Genmab A/S (GMAB) Announces EPKINLY Approved by Japan ... - StreetInsider.com
Mon, 25 Sep 2023
EPKINLY™ (epcoritamab) Approved by Japan Ministry of Health ... - Galveston County Daily News
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
653 (M) |
| Shares Float |
645 (M) |
|
% Held by Insiders
|
0 (%) |
|
% Held by Institutions
|
6.6 (%) |
|
Shares Short
|
2,890 (K) |
|
Shares Short P.Month
|
4,190 (K) |
Stock Financials |
|
EPS
|
1 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
44.04 |
|
Profit Margin (%)
|
29 |
|
Operating Margin (%)
|
40.1 |
|
Return on Assets (ttm)
|
13.8 |
|
Return on Equity (ttm)
|
17.8 |
|
Qtrly Rev. Growth
|
32.7 |
|
Gross Profit (p.s.)
|
22.35 |
|
Sales Per Share
|
25.06 |
|
EBITDA (p.s.)
|
10.61 |
|
Qtrly Earnings Growth
|
-28.2 |
|
Operating Cash Flow
|
6,040 (M) |
|
Levered Free Cash Flow
|
3,660 (M) |
Stock Valuations |
|
PE Ratio
|
36.17 |
|
PEG Ratio
|
0.1 |
|
Price to Book value
|
0.82 |
|
Price to Sales
|
1.45 |
|
Price to Cash Flow
|
3.95 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
